EVMN FY 2024 Earnings — Evommune, Inc. Revenue & Financial Results | Market Cap Arena

EVMNEvommune, Inc.

$319M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+40.0% YoY

Gross Profit

$6M81.6% margin

Operating Income

-$70M-1000.2% margin

Net Income

-$67M-954.4% margin

EPS (Diluted)

$-2.27

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$58M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$76M

Total Liabilities

$220M

Stockholders' Equity

-$144M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$5M	+40.0%
Gross Profit	$6M	$4M	+42.8%
Operating Income	-$70M	-$38M	-85.0%
Net Income	-$67M	-$34M	-96.2%